When it comes to value-based care, Saudi Arabia is still at an early phase, but we are on the right track. We expect the local healthcare…
In Conversation
One of the key messages in terms of new therapies for childhood cancer is that clinical studies should be both demanded of industry and expected to…
There is a huge gap in the distribution of healthcare globally, with two-thirds of the world's population lacking access to basic diagnostic imaging
During the pandemic, it became evident to hospital groups that having a partner that can offer a broad portfolio was a key advantage. We are currently…
While scaling our company by uniting with others would make us more competitive on a global scale, we still believe it is possible to be successful…
We are trying to overcome the idea that robotic systems are difficult to adopt with a steep learning curve; they can improve the clinical outcomes of…
We are calling strongly for a greater role in ensuring that the right treatments are approved, the ones that matter most to patients. The only way…
The main differentiating factor for Abdi Ibrahim among Turkish companies is our willingness to invest in, and collaborate with, international players
We are close to having the technological capacity to develop all types of biosimilar products, even some novel ones
The medical infrastructure in Turkey is substantial with many large hospitals. However, for clinical trials, we need more dedicated places to conduct clinical trials, an institutional…
Almost 50 percent of clinical trials in the region last year were led by biotechs and by 2025, biotech-led clinical trials will far exceed those led…
The Turkish authorities continue to be content with the current [pricing] system because it has been sustained until today. The question the industry is asking itself…
